STAT

Alexion’s newly approved rare-disease drug notches another clinical trial win

Alexion's newly approved rare-disease drug notches another clinical trial win — this time in patients with a rare type of kidney disease.
Source: Kristoffer Tripplaar/SIPA/AP

Alexion Pharmaceuticals (ALXN) said Monday that its newly approved drug Ultomiris achieved the primary goal of a late-stage clinical trial involving patients with a rare type of kidney disease.

Based on the successful outcome of the clinical trial,

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
How Europe Is Building A Sweeping System To Study Medication Safety In Pregnant And Lactating Women
More than 88 organizations have joined a sweeping new effort in Europe to tackle the research gaps on medication use in pregnant and lactating women.
STAT4 min read
Alarmed By New ‘CRISPR Babies’ Plan, Top Science Figures Say They’re Powerless To Stop It
Outraged by a new plan to create "CRISPR babies" in Russia, leading science figures concede that their organizations are powerless to stop it.
STAT2 min read
Rivals’ Disappointing Results In Asthma Trial Drag Down Shares Of AnaptysBio
Disappointing clinical trial results from Sanofi and Regeneron raise questions about the future role that certain drugs might have in treating asthma and other inflammatory related diseases.